http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-102014013451-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_448f8c8c395bc367f28833558250f22f |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-40 |
| filingDate | 2014-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96e63f9db0c2b64b7afa9d6df6890e32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b4cd45d12503ea451a0e20621e31b18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6623a8298294f579e0231a795b26bb2c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_47190f1d33f47c4a089a5f07f8e7717f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a2d817485a982acbf4a82827ee5bda9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c7091c369cd965b0508ef92076d10c4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2fe66bd1b2e18f319c67abd36870986 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbc523453f91bb14efeaceb35c92f06f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c30048b02edb5f5f65b398c207811d6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a8f4dcb831975fd8d1bd6ab87948c06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bc4a656abd26bc00bbff7c64de928c1 |
| publicationDate | 2016-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-102014013451-A2 |
| titleOfInvention | pharmaceutical preparation containing carvacrol with b-cyclodextrin with antiinflammatory and antinociceptive property |
| abstract | pharmaceutical preparation containing carvacrol with b-cyclodextrin with anti-inflammatory and antinociceptive property. The present invention relates to a novel formulation for use of carvacrol, the carvacrol b-cyclodextrin inclusion complex. It is a formulation whose active ingredient, carvacrol, complexed with b-cyclodextrin presents, in low doses, anti-inflammatory and antinociceptive properties in skeletal muscle injury model, reducing patient risks and treatment costs. Although this is an important clinical condition, pharmacological treatment for muscle inflammation still remains associated with numerous adverse effects, involves high costs and is often unsatisfactory, thus resulting in functional and labor disabilities. Therefore, the carvacrol inclusion complex with b-cyclodextrin represents a promising utility model, since the complexation guarantees the anti-inflammatory and antinociceptive effect of carvacrol even under low doses when administered orally. The present pharmaceutical formulation of the inclusion complex was tried at doses of 2.5 mg / 10 mg / kg and 20 mg / kg of carvacol. Results were obtained demonstrating the therapeutic advantage of using the compound in the complex inclusion form. |
| priorityDate | 2014-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 126.